Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | PRADO: personalized response-driven surgery and adjuvant therapy in stage III melanoma

Sunandana Chandra • 15 Jun 2020
ASCO 2020
Melanoma Skin Cancer Ipilimumab Nivolumab

Sunandana Chandra, MD, MS, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, reviews data reported from the PRADO study (NCT02977052). This phase II study investigated personalized response-driven surgery and adjuvant therapy following neoadjuvant ipilimumab and nivolumab in patients with resectable stage III melanoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Sunandana Chandra

3:14
Repurposing irinotecan
Sunandana Chandra • 11 Jun 2020
1:33
FIH study of ARV-110 in metastatic castrate-resistant prostate cancer
Sunandana Chandra • 11 Jun 2020
2:47
Intrathecal + IV nivo for metastatic melanoma with leptomeningeal disease
Sunandana Chandra • 16 Jun 2020
2:19
Toripalimab + axitinib in patients with metastatic mucosal melanoma
Sunandana Chandra • 15 Jun 2020

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals